Aim. The objective of the present study was to evaluate the effectiveness of the courses of therapy and the maintenance treatment of erosive reflux-esophagitis with the use of dexlansoprazole (dexilant) in the patients presenting with «acid» reflux. Material and methods. The study included 67 patients of the mean age 54.3±16.4 years (45 men and 22 women) presenting with «acute» reflux in whom esophagogastroduodenoscopy (EGDS) revealed erosive esophagitis whereas the immunohistochemical study has failed to identify a persistent infection with the herpes group viruses. The severity of erosive esophagitis was estimated based on the Savary—Miller (S—M) classification. The patients were allocated to two groups. The study group was comprised of 34 patients treated with dexilant at a dose of 60 mg once daily regardless of the meal time for 8 weeks (56 days) while the control group consisted of 55 patients given omeprazole at a dose of 20 mg twice daily before meal as the main treatment during the same period. After the termination of the main course of therapy and the achievement of complete re-epithelization of the eroded areas, the patients of the study group were given the maintenance treatment with dexilant at a dose of 30 mg once daily without regard to timing of food ingestion whereas the patients of the control group were treated with omeprazole at a dose of 20 mg once daily 30 minutes before the meal. The duration of the maintenance therapy in either group was 8 weeks (56 days). Results. Three types of complaints could be distinguished prior to the onset of the treatment, viz. heartburn in 76.5% of the patients with «acute reflux», gaseous eructation in 58.8% of them , and regurgitation in 47.1% of the patients. The frequency and intensity of all the three conditions were significantly reduced during the course of therapy The heartburn practically disappeared within 56 days after the initiation of therapy in the patients of the study group as compared with those of the control group (р<0,05) while the number of the patients complaining of gaseous eructation and regurgitation decreased to 8.8% and 14.7% respectively and was significantly lower than before the treatment (р<0,05). Epithelization of the eroded areas and ulcer cicatrization were documented in 79.4% of the patients of the study group within 28 days after the onset of the treatment in comparison with the patients of the control group (р<0,05). By the end of the basal therapy 100% of the patients underwent complete endoscopic remission. Likewise, the maintenance therapy was accompanied by positive dynamics of the patients’ conditions. No cases of recurrent heartburn were documented. Conclusion. The present study has demonstrated the effectiveness and safety of dexilant therapy at a dose of 69 mg for the management of the patients presenting with the erosive form of gastrointestinal reflux disease (GERD). The analysis of the comparative efficiency showed that a course of therapy 56 days in duration resulted in epithelization of the defects of esophageal mucosa in 100% of the treated patients with the simultaneous disappearance of heartburn, the main symptom responsible for the deterioration of the quality of life. The dose of 30 mg of Dexilant therapy is sufficient to achieve the beneficial outcome of the treatment and prevent the recurrent erosive-ulcerative lesions of the mucous membrane of the oesophagus and the related clinical symptoms. The patients described the daily intake of this medication without regard to timing of food ingestion as a convenient mode of treatment which is likely to promote the high degree of compliance with the prescribed therapy.